To generate mutations at the APTF-2 target site in the glp-1 promoter we injected the following mix: Cas9 protein (5 g), tracrRNA (0.4 g/l), crRNA (aatgggcggagtatgccacc) (0.4 g/l), ssDNA oligo repair donor (1 g/l), myo-2::mCherry plasmid (4 ng/l) and brought to a 20 l volume with nuclease-free water
En total participaron 45 personas , de las cuales 29 recibieron el procedimiento activo y 16 el placebo
This large-scale observational study highlights potential shared inflammatory or metabolic pathways, reinforcing the need for greater clinical awareness and further investigation
Verify benefits with the clinic and your insurer
If you are scheduled for surgery or a procedure requiring sedation, tell your anesthesia provider you are on a GLP-1 medication
Schedule your appointment today , and let us guide you on your path to success